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Abstract
Background: Results from trials of intermittent preventive treatment (IPT) in infants and children have shown that IPT
provides significant protection against clinical malaria. Sulfadoxine-pyrimethamine (SP) given alone or in combination with
other drugs has been used for most IPT programmes. However, SP resistance is increasing in many parts of Africa. Thus, we
have investigated whether SP plus AQ, SP plus piperaquine (PQ) and dihydroartemisinin (DHA) plus PQ might be equally
safe and effective when used for IPT in children in an area of seasonal transmission.
Methods: During the 2007 malaria transmission season, 1008 Gambian children were individually randomized to receive SP
plus amodiaquine (AQ), SP plus piperaquine (PQ) or dihydroartemisinin (DHA) plus PQ at monthly intervals on three
occasions during the peak malaria transmission season. To determine the risk of side effects following drug administration,
participants in each treatment group were visited at home three days after the start of each round of drug administration
and a side effects questionnaire completed. To help establish whether adverse events were drug related, the same
questionnaire was administered to 286 age matched control children recruited from adjacent villages. Morbidity was
monitored throughout the malaria transmission season and study children were seen at the end of the malaria transmission
season.
Results: All three treatment regimens showed good safety profiles. No severe adverse event related to IPT was reported.
The most frequent adverse events reported were coughing, diarrhoea, vomiting, abdominal pain and loss of appetite.
Cough was present in 15.2%, 15.4% and 18.7% of study subjects who received SP plus AQ, DHA plus PQ or SP plus PQ
respectively, compared to 19.2% in a control group. The incidence of malaria in the DHA plus PQ, SP plus AQ and SP plus PQ
groups were 0.10 cases per child year (95% CI: 0.05, 0.22), 0.06 (95% CI: 0.022, 0.16) and 0.06 (95% CI: 0.02, 0.15) respectively.
The incidence of malaria in the control group was 0.79 cases per child year (0.58, 1.08).
Conclusion: All the three regimens of IPT in children were safe and highly efficacious
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Introduction
Although significant advances have been made in controlling
malaria during the last two decades, the disease remains a major
cause of mortality and morbidity in sub-Saharan Africa. The most
important recent steps in improving malaria control include the
introduction of artemisinin-based combination therapy (ACT),
intermittent preventive treatment (IPT) in pregnancy and
increased coverage with ITNs. However, malaria is still estimated
to cause directly nearly one million deaths a year and the vast
majority of deaths occur among young children, especially among
those living in remote rural areas of Africa [1]. The global malaria
control strategy includes prompt treatment with effective drugs,
effective use of insecticide treated materials, and more recently, a
revival in the use of indoor residual spraying (IRS). In addition, the
strategy of intermittent preventive treatment (IPT) has become an
integral part of malaria control in pregnancy. The IPT principle
has subsequently been extended to include infants (IPTi) [2] and
children (IPTc) [3]. Recently, IPT in infants was endorsed by
WHO as a recommended malaria control strategy in areas with
moderate or high transmission and a low prevalence of resistance
to sulphadoxine/pyrimethamine (SP).
The role of IPT in the prevention of malaria and anaemia in
children has been evaluated in a limited number of trials. In
Mali, an area of seasonal malaria transmission, two doses SP
given to children aged 6 months to 9 years at an interval of two
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months gave a protective efficacy of 40% against clinical attacks
of malaria [4]. In another study undertaken in Niakhar,
Senegal, an area of intense but short seasonal malaria
transmission, SP plus one dose of artesunate (AS) given to
children less than 5 years old three times at one monthly
intervals throughout the peak period of malaria transmission
Figure 1. Trial profile.
doi:10.1371/journal.pone.0011225.g001
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season resulted in an 86% reduction in clinical malaria [3].
Another trial undertaken in Niakhar, Senegal, compared four
different treatment regimens. The combinations investigated
were SP plus one dose of AS, SP plus three doses of AS, SP plus
three doses of amodiaquine (AQ) and three doses of AS plus
AQ. The best results were obtained with SP plus three doses of
AQ. This regimen showed the highest level of protection against
infection and the lowest prevalence of parasitaemia at the end of
the malaria transmission season [5]. In another comparative
IPTc study undertaken in Ghana, monthly AQ plus AS was
compared with bimonthly AQ plus AS and bimonthly SP.
Monthly AS plus AQ was the most effective regimen, giving
69% protection against clinical episodes of malaria [6]. These
results suggest that IPTc has potential as an affordable malaria
and anaemia control tool. SP has been used widely for IPT
because of its long half-life, safety, wide availability, low-cost,
ease of delivery (a single dose treatment) and a good
acceptability profile. However, resistance to SP is increasing,
especially in East Africa. . Thus, there is a need to find
alternative drugs for IPT.
We have, therefore, undertaken a clinical trial in which the
safety, tolerability and efficacy of SP plus AQ, SP plus piperaquine
(PQ) and dihydroartemisinin (DHA) plus (PQ) have been
compared when used for intermittent preventive treatment in
children in an area of seasonal transmission.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study site and population
The study was based at the MRC Field Station, Basse in the
Upper River Region of The Gambia and was conducted between
May 2007 and December 2008. Malaria in The Gambia is highly
seasonal, occurring almost exclusively during the rainy season (July
to November) with greatest incidence in October to November
[7]. The entomological inoculation rate is estimated to be in the
range of 1 to 50 infective bites per person per year [8]. During the
course of the study, first line treatment for uncomplicated malaria
in The Gambia was chloroquine plus SP. In 2001, the PCR-
corrected treatment failure rate in symptomatic children at day 28
after the start of treatment with SP and chloroquine was 6% in the
central part of the country [9]. Since 2008, the first line treatment
for uncomplicated malaria has been lumefantrine-artemether
(CoartemTM, Novartis Pharma, and Basel Switzerland).
Study Design
The study was designed as an open-label, randomized trial.
One thousand and eight children were individually randomized
to receive SP plus AQ, SP plus PQ or DHA plus PQ (Duo-
CotecxinH) at monthly intervals on three occasions during the
peak malaria transmission season ( September, October, and
November). IPTc has been shown to reduce morbidity from
malaria in children substantially. Thus, it was considered ethically
unacceptable to include a randomized placebo group in the
study. For this reason, an alternative design was chosen that
relied upon recruitment of children aged 6–59 months from
adjacent villages (less than 10 km from a study village). Using the
data provided through an on-going Demographic Surveillance
System (DSS) 286 children matched for age to children in the
trial were randomly selected from 9 adjacent villages to form a
control group.
Screening, enrolment and drug distribution
Meetings were held in the villages in the study area to provide
information about the trial to parents of potential study
participants and to seek community consent. Fourteen villages
agreed to participate in the study; the average distance to the
nearest health centre of these villages was approximately 5 km. A
list of children living in the study villages and who would be aged
between 6 and 59 months at the time of the first treatment in
September 2007 was obtained from the Basse DSS. These
children and their parents were invited for screening for potential
participation in the trial between July and August 2007. Written
informed consent was obtained from parents or guardians of all
study subjects before screening. Children had their age and
identities checked, and were examined to rule out any clinically
significant disease. Finger-prick blood was collected for prepara-
tion of a thick blood smear and measurement of haemoglobin
concentration. Children were considered eligible if they had no
clinically significant chronic or acute disease. Exclusion criteria
included known allergy to any antimalarial drug or presence of
acute or chronic, clinically significant pulmonary, cardiovascular,
Table 1. Loss to follow up by baseline characteristics and
treatment group.
N No. %
Age (months)
,12 6 0 0
12–23 160 4 2.5
24–35 268 4 1.5
36–47 248 6 2.4
48+ 318 7 2.2
Total 1000 21 2.1 P = 0.876
Weight (Kg)
6–10 198 4 2
10–14 550 11 2
14–18 242 6 2.5
18–22 15 0 0
Total 1005 21 2.1 P = 0.967
Asexual parasitaemia
No 992 21 2.1
Yes 13 0 0
Total 1005 21 2.1 P = 0.759
Hb ,9g/dL
,9 229 3 1.3
.=9 767 18 2.3
Total 996 21 2.1 P = 0.439
ITN usage
Yes 683 11 1.6
No 322 10 3.1
Total 1005 21 2.1 P = 0.155
Treatment group
SPplusAQ 336 8 2.4
DHAplusPQ 336 11 3.3
SPplusPQ 336 5 1.5
Total 1008 24 2.4 P = 0.338
doi:10.1371/journal.pone.0011225.t001
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hepatic or renal disease. Blood films were examined shortly after
collection from any child with symptoms suggestive of malaria
whilst remaining blood films were examined at a later date.
Children with acute malaria were treated with CoartemTM and
excluded from the study.
One thousand and eight eligible children whose parents
consented were individually randomized into the SP plus AQ,
SP plus PQ or DHA plus PQ treatment groups in a 1:1:1 fashion.
A photo ID card was given to all participants to facilitate
identification at every subsequent contact, at home or in the health
centres. The randomization list was generated using permuted
blocks of 12, using the random number generator of STATA
version 10. Treatment assignments were placed in sealed opaque
envelopes labelled with the randomization number, each child
enrolled was assigned the next study number in sequence.
Monthly treatment was given at the nearest health centre by a
team of two nurses who played no part in the evaluation of safety
or efficacy measurements and who did not communicate any
information on group allocation to the team in charge of the
evaluation of adverse events and morbidity. Children received half
a tablet of SP [tablets containing 25 mg pyrimethamine and
500 mg sulphadoxine] (Micro Labs Ltd, Hosur, India) if they
weighted 10 kg or less and a whole tablet if they weighed more
than 10 kg. Amodiaquine [200 mg base tablets] (Micro Labs Ltd,
Hosur, India) was given as follows; K, K and J tablets on days
1,2 and 3 for children who weighed 10 kg or less and 1,1 and K
tablets on days 1,2 and 3 for children who weighed more than
10 kg. Piperaquine [tablets containing 250 mg] (Shanghai Phar-
maceutical Co., Shanghai, China) was given at a dose of half a
tablet for children who weighed 11 kg or less and as a whole tablet
if a child’s weight was more than 12 kg. Duo-CotecxinH [tablets
containing 40 mg of DHA and 250 mg PQ] ( Holleykin
Pharmaceutical Co. Ltd., Guangzhou, China) was given at a dose
of half a tablet for children who weighed 13 kg or less and a whole
tablet for children who weighed more than 13 kg.
To ensure compliance with European regulations regarding drug
quality, a sample of PQ tablets was tested for drug content and
impurities by Sigma Tau Pharmaceutical company; drug concen-
tration was within 5% of the nominal level and analysis of impurities
indicated that although some impurities exceeded the ICH limit for
known impurities [EMA, 2006], all these impurities were identified
and none were of concern in terms of safety. The solubility and drug
content of the SP and AQ tablets was confirmed by analysis with
high performance liquid chromatography at the London School of
Hygiene & Tropical Medicine, which was also used after the trial to
confirm that drugs had been allocated to the correct group in
accordance with the randomization code. Tablets were crushed,
mixed with honey or suspended in water and given on a spoon. All
participants were kept under observation for 30 minutes after drugs
were taken. If vomiting occurred during this period, the full dose of
treatment was re-administrated. If a child vomited the second
administration treated was not repeated but he/she was allowed to
stay in the trial.
Surveillance for adverse events
To determine the proportion of children who experienced an
adverse event such as headache, fever, weakness, abdominal pain,
anorexia, nausea, vomiting, diarrhoea, rash, itching or sleep
disorder following drug administration, study participants were
visited at home three days after the start of each round of drug
administration and a side effects questionnaire completed to
document and quantify adverse events that might have occurred
since receiving the trial medication. Grading of the severity of
adverse events was done by trained field workers. An adverse
reaction was graded as mild (grade 1) if it was easily tolerated,
moderate (grade 2) if it interfered with normal activity and severe
(grade 3) if it prevented normal activity and required treatment.
To help establish whether adverse events were drug related or
coincidental, the same questionnaire was administered to children
in the control group on completion of each treatment round.
Morbidity surveillance during the rainy season
Passive surveillance for malaria was maintained throughout the
transmission season for 16 weeks (September to December).
Parents/guardians of children in the trial and controls were
encouraged to take their child to the health centre identified as
being closest to their home ( all the health centres in the study area
Table 2. Number of doses of trial medication received and compliance.
SPplusAQ (n=336) DHAplusPQ (n=336) SPplusPQ (n=336)
No. % No. % No. %
No. first doses completed
0 0 0 1 0.3 1 0.3
1 5 1.5 7 2.1 4 1.2
2 73 21.7 39 11.6 37 11
3 258 76.8 289 86 294 87.5
Home dose taken (Sept)
No 51 15.2 25 7.4 40 11.9
Yes 285 84.8 311 92.6 296 88.1
Home dose taken (Oct)
No 57 17 37 11 43 12.8
Yes 279 83 299 89 293 87.2
Home dose taken (Nov)
No 57 17 27 8 29 8.6
Yes 279 83 309 92 307 91.4
doi:10.1371/journal.pone.0011225.t002
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were within walking distance or could be easily reached by local
transport) at any time that their child became unwell. Project staff
were based at each of these health facilities to identify children in
the trial and to ensure that they were seen, properly investigated
and treated promptly. At each clinic visit, axillary temperature was
recorded using a digital thermometer and haemoglobin concen-
tration measured. A dipstick for diagnosis of malaria (CORE
Diagnostics, Birmingham, UK) was used if fever (axillary
temperature of $37.5uC) or a history of fever within the previous
48 hours was present. In such cases, a thick blood smear was also
collected for subsequent confirmation of the diagnosis. Study
subjects with documented fever or history of recent fever and
malaria parasitaemia were treated with CoartemTM. The
treatment of study subjects seen at the health centres for other
conditions was carried out in accordance with national guidelines
and a standardized form was used to document details of the
illness and treatment received.
Children enrolled in the study were seen at a health centre at
the end of malaria transmission season for examination by a study
physician and a finger-prick blood sample was obtained for
preparation of a thick blood smear and determination of
haemoglobin concentration. A standardized questionnaire was
administered to the parents/guardians of the study subject to
collect information regarding any illness that had occurred since
the last visit, symptoms experienced, use of healthcare facilities and
use of medicines.
Laboratory methods
Thick smears were prepared in duplicate so that if the subject
had symptoms of malaria, one smear could be stained with Field’s
stain and read promptly to guide treatment. The other smear was
stained with Giemsa stain and 200 high power fields (HPF) were
examined before a smear was declared negative. Only the Giemsa-
stained slide readings were used for the trial analysis. Parasite
density was expressed per ml with the assumption that 1 parasite
per high-powered field (hpf) equals 500 parasites per ml [10]. All
slides were read by two laboratory technicians. If there was
disagreement between their readings on parasite positivity or if the
difference in the log-densities recorded was more than 1.5, slides
were read by a third technician. Agreement was reached among
the three microscopists after the slides had been re-checked.
Discrepancies occurred mainly in smears with very low parasite
densities. During follow-up, when a laboratory technician was not
available to read a thick blood smear for malaria parasites, the
CoreTM Malaria Pf test (CORE Diagnostics, Birmingham, UK)
was used to guide treatment and, a thick blood smear was collected
for subsequent confirmation of the diagnosis.
Haemoglobin concentration was measured at recruitment,
during morbidity surveillance and at the end of malaria
transmission season surveys using a portable haemoglobinometer
(HemoCue AB, Sweden).
Statistical analysis
The primary study endpoint was the proportion of children who
reported an adverse event during at least one of the three follow up
surveys. Secondary endpoints were the number of clinic
attendances with malaria during the surveillance period and the
mean Hb concentration and the prevalence of asexual parasitae-
mia recorded in the cross-sectional survey in December. Sample
size was calculated for comparison of each treatment group to the
group that received SP plus AQ, the best regimen identified in a
previous trial conducted previously in Niakhar, Senegal [5]. Based
on previous experience, we assumed that the frequency of adverse
event in the SP plus AQ group would be 15 to 20%. A trial with
286 children per arm has over 80% power to detect a halving in
the frequency of adverse events, using a significance of 0.025 (to
preserve an overall type 1 error rate of 5% for the primary
endpoint when there are 2 comparisons, each alternative drug
group to be compared with SP plus/ AQ). Based on experience
from several previous studies, the drop-out rate was not expected
to exceed 15%. Allowing for a 15% drop out, a sample size of
28663/(120.15) = 1009 was therefore needed.
The primary analysis included all individuals who were
allocated to treatment provided and who were followed up at
the three visits that they received at least one follow-up visit,
regardless of the number of treatments received. Data were
analysed according to the treatment group to which a child was
allocated. The prevalence of each type of adverse event was
computed for the different treatment and control groups and
presented with an exact binomial confidence interval. Fisher’s
exact test was used to test for differences in prevalence between the
Table 3. Baseline characteristics at enrolment by treatment
group.
SP plus AQ DHA plus PQ SP plus PQ
No. % No. % No. %
Age (months)
,12 1 0.3 3 0.9 2 0.6
12–23 56 16.8 51 15.3 53 15.9
24–35 95 28.5 86 25.8 87 26
36–47 78 23.4 86 25.8 84 25.1
48+ 103 30.9 107 32.1 108 32.3
Total 333 100 333 100 334 100
Age (mean, range) 38.79 (0,69) 39.35 (0,72) 39.43 (5,68)
Weight ( Kg)
6–10 79 23.6 59 17.6 60 17.9
10–14 178 53.1 189 56.4 183 54.6
14–18 72 21.5 81 24.2 89 26.6
18–22 6 1.8 6 1.8 3 0.9
Total 335 100 335 100 335 100
Weight (mean, SD) 12.12 (2.61) 12.36 (2.56) 12.36 (2.57)
Asexual parasitaemia
No 333 99.4 327 97.6 332 99.1
Yes 2 0.6 8 2.4 3 0.9
Total 335 100 335 100 335 100
Hb ,9g/dl
Yes 81 24.3 63 19 85 25.6
No 252 75.7 268 81 247 74.4
Total 333 100 331 100 332 100
Hb (mean,SD) 10.09 (1.65) 10.39 (1.69) 10.13(1.71)
ITN usage
Yes 221 66.0 228 68.1 234 69.9
No 114 34.0 107 31.9 101 30.1
Total 335 100 335 100 335 100
*The mean age of children in the control group was 37.7 months (range :12, 68)
and 5%, 20.1%, 23.8%, 25.2% and 30.4% were in the ,12 months, 12–23
months, 24–35 month, 36–47 months and 48+ months age groups
respectively.
doi:10.1371/journal.pone.0011225.t003
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treatment groups. The overall frequency of adverse events was
computed separately for each month and a Chi-square test for
trend was used to test for a time trend in the prevalence of adverse
events.
For the secondary analysis, malaria incidence was estimated for
the treatment and control groups. To do this we calculated the
total child years of follow-up in each group and the number of first
cases of malaria. Rates were calculated with exact confidence
intervals based on the Poisson distribution. For rate ratios, exact
Poisson regression was used to obtain confidence intervals. All
treated cases with parasitaemia at any density were included in the
analysis of efficacy. Differences in mean Hb concentrations
between treatment groups in December were estimated using
analysis of covariance, adjusting for the Hb measurement at
enrolment. All analyses were done with STATA software version
10 (College Station, TX, USA).
Ethical review
The study was approved by the London School of Hygiene &
Tropical Medicine ethics committee and by the joint MRC/
Gambia Government ethics committee.
Results
One thousand two hundred children aged 6–59 months were
screened and allocated to receive monthly IPT with SP plus AQ,
SP plus PQ or DHA plus PQ. One thousand and eight children
(84%) who were enrolled, treated and followed up for at least one
visit were included in the primary analysis. The first dose of IPT
treatment was given between 13–24 September 2007, the second
dose between 16–26 October and the final dose between 13–24
Novembers. A cross-sectional survey was carried out between 6–
13 December 2007. One of these 1008 children died in a road
traffic accident and a further 23 were lost to follow up before the
end of the surveillance period (Figure 1). Loss to follow up was
similar among the treatment groups and was not associated with
any of the baseline characteristics (Table 1). Among the 1008
included in the analysis, 331, 328, and 331 children received at
least 2 treatments of SP plus AQ, SP plus PQ and DHA plus PQ
respectively (Table 2). At enrolment the three treatment groups
were similar with respect to variables such age, bednet usage,
mean weight or mean haemoglobin concentration (Table 3).
Plasmodium falciparum parasitaemia was found infrequently at
enrollment.
Compliance with IPTc
Table 2 shows the number of children who came for their
scheduled monthly treatment and the corresponding compliance
during the malaria transmission period. The number of children
who received the first dose of chemoprevention at the health
centre was similar in the three treatment groups. However, the
number of children who completed all the three doses was less in
the SP plus AQ treatment group (77%) compared to the SP plus
PQ (87.5%) and DHA plus PQ (86%) groups (chi-square = 16.4,
df = 2, p-value,0.001). In addition, more children in the SP plus
AQ group failed to complete their monthly treatment at home
compared to those in the SP plus PQ and DHA plus PQ groups.
(September, chi-square = 9.96, 2df, P = 0.007; in October, chi-
square = 52.2, 2df, P,0.001; in November, chi-square = 16.8, 2df,
P=,0.001).
Safety and tolerability
Field workers visited study subjects three days after the start of
each treatment round to document the incidence of adverse
reactions. A summary of solicited adverse events is provided in
Table 4. Monthly treatment with the three treatment regimens
was generally well tolerated. No severe adverse reactions
attributable to the study drugs, such as anaphylaxis, were detected
in any volunteer during the study period. No severe skin reaction
was reported in any child at any stage of the trial. The most
frequent adverse events reported were coughing, diarrhoea,
vomiting, loss of appetite and abdominal pain. Coughing was
present in 15.2%, 15.4% and 18.7% of study subjects who
received SP plus AQ, DHA plus PQ and SP plus PQ respectively,
Table 4. Percentage of children with a solicited adverse event during one or more of the treatment rounds.
SPplusAQ (n=329) DHAplusPQ (n=325) SPplusPQ (n=331) Controls (n =286)
Symptom No. % (95% CI) No. % (95% CI) No. % (95% CI) No. % (95% CI) *p-value
Abdominal pain 22 6.5(4.1,9.7) 21 6.3(3.9,9.5) 19 5.7(3.4,8.7) 36 12.5(8.9,16.9) 0.89
Diarrhoea 45 13.4(9.9,17.5) 44 13.2(9.7,17.3) 34 10.1(7.1,13.9) 50 17.4(13.2,22.3) 0.34
Drowsiness 2 0.6(0.1,2.1) 1 0.3(0,1.7) 2 0.6(0.1,2.1) 4 1.4(0.4,3.5) 1.00
Headache 9 2.7(1.2,5) 9 2.7(1.2,5.1) 14 4.2(2.3,6.9) 23 8.0(5.1,11.8) 0.49
Itching 14 4.2(2.3,6.9) 15 4.5(2.5,7.3) 17 5.1(3.0,8.0) 21 7.3(4.6,11) 0.86
Jaundice 5 1.5(0.5,3.4) 2 0.6(0.1,2.1) 3 0.9(0.2,2.6) 3 1.0(0.2,3.0) 0.62
Loss appetite 28 8.3(5.6,11.8) 22 6.6(4.2,9.8) 25 7.4(4.9,10.8) 37 12.9(9.2,17.3) 0.69
Malaise 9 2.7(1.2,5) 9 2.7(1.2,5.1) 11 3.3(1.6,5.8) 15 5.2(3.0,8.5) 0.92
Nausea 7 2.1(0.8,4.2) 7 2.1(0.8,4.3) 6 1.8(0.7,3.8) 10 3.5(1.7,6.3) 0.96
Skin rash 10 3(1.4,5.4) 10 3(1.4,5.4) 15 4.5(2.5,7.3) 26 9.1(6.0,13.0) 0.52
Sleep disorder 4 1.2(0.3,3) 7 2.1(0.8,4.3) 9 2.7(1.2,5.0) 12 4.2(2.2,7.2) 0.39
Vomiting 19 5.7(3.4,8.7) 17 5.1(3.0,8.0) 25 7.4(4.9,10.8) 38 13.2(9.5,17.7) 0.43
Cough 51 15.2(11.5,19.5) 51 15.3(11.6,19.6) 63 18.8(14.7,23.3) 55 19.2(14.8,24.2) 0.38
Any 129 38.4(33.2,43.8) 134 40.1(34.8,45.6) 141 42(36.6,47.4) 158 55.1(49.1,60.9) 0.65
*p-value from a comparison of the three treatment groups using Fisher’s exact test.
% refers to the proportion of children who reported an adverse event on any occasion after drug administration.
doi:10.1371/journal.pone.0011225.t004
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compared to 18.9% in the control group. 13.3%, 13.2%, and
10.3% of children in the SP plus AQ, DHA plus PQ and SP plus
PQ groups respectively developed diarrhoea, compared to 17.5%
in the control group. Loss of appetite was present in 8.2%, 6.4%
and 7.2% of children in the SP plus AQ, DHA plus PQ and SP
plus PQ groups respectively, compared to 13.1% in the control
group. In general, symptoms were more common in the control
group than in the three treatment groups. No grade 3 adverse
events were reported in any treatment group during the follow-up
period. Three children in the DHA plus PQ and one child in SP
plus AQ group were admitted to hospital because of an acute
respiratory infection. One child in the SP plus PQ group
developed a febrile convulsion. One child in the SP plus AQ
group was treated for severe dehydration. Only one child, who was
in the DHA plus PQ group, died as a result of a road traffic
accident.
To test whether the risk of reported adverse events varied with
the number of doses received, separate analyses were carried out
for each of the treatment rounds and the results showed significant
decrease in the risk of adverse events in the SP plus PQ group
when measured after the 2nd and 3rd dose compared to the first
round (Table 5).
Malaria incidence
The incidence of clinical attacks of malaria was generally low in
all the treatment groups; overall incidence of malaria among
children in the trial was 0.22 per child year (95% CI 0.16, 0.28).
No child had more than one episode of malaria. The incidence of
malaria in the DHA plus PQ, SP plus AQ and SP plus PQ groups
was 0.10 (0.05, 0.22), 0.06 (0.022, 0.155) and 0.06 (0.02, 0.15)
respectively. The incidence of malaria in the non-randomized
control group measured by passive case detection was 0.79 (0.58,
1.08) [Tables 6 and 7]. The percentage reduction in incidence
compared to the control group was 87% (95%CI 71%, 95%) for
DHA plus PQ, 93% for SP plus AQ and 93% (80%, 98%) for SP
plus PQ).
Cross-sectional survey at the end of the malaria
transmission season
Ninety-seven percent (982/1008) of the study children (328 SP
plus AQ, 324 DHA plus PQ, 330 SP plus PQ) were seen during
the end of the rainy season survey when blood samples for
determination of parasitaemia and haemoglobin were collected.
The prevalence of parasitaemia was very low (0.3% SP plus AQ,
2.2% DHA plus PQ, 0.6% SP plus PQ). Mean Hb concentration
was similar in the three groups (10.1 g/dL SP plus AQ, 10.4 g/dL
DHA plus PQ, 10.1 g/dL SP plus PQ) [Table 8]. Moderate
anaemia was present in 4%, 5% and 7% of the children in SP plus
AQ, DHA plus PQ and SP plus PQ treatment groups respectively.
Four children were severely anaemic (Hb ,5 g/dL) at the time of
the December survey, two in SP plus PQ group and one each in
SP plus AQ and DHA plus PQ groups.
Discussion
In this study, we have compared the safety, tolerability and
efficacy of three potential drug combinations for intermittent
preventive treatment of malaria in children. All three treatment
regimens investigated, including the one used in the previous
Senegalese trial (SP plus AQ), were safe and efficacious. The
incidence of malaria during the trial and the prevalence of
parasitaemia at the end of the malaria transmission season were
very low in all the three treatment groups. These results are
consistent with findings from previous trials of IPTc carried out in
other West African countries which showed significant levels of
protection against clinical attacks of malaria during the malaria
transmission season [3,4,6]. Overall, 68% of the study subjects
used insecticide-treated bednets (ITNs), and it is possible the
widespread use of ITNs contributed to the low incidence of clinical
attacks of malaria observed in this trial.
All three combination investigated were safe. No serious adverse
event attributable to study medication was observed. Minor
adverse events observed in this trial occurred infrequently in all the
Table 6. Incidence of malaria by treatment group (any
parasitaemia).
Cases Child years Rate (95% CI)
Control 41 51.81 0.79 (0.57–1.07)
SP plus AQ 4 68.81 0.06 (0.02–0.15)
DHA plus PQ 7 67.84 0.10 (0.04–0.21)
SP plus PQ 4 69.60 0.06 (0.02–0.15)
doi:10.1371/journal.pone.0011225.t006
Table 7. Incidence of malaria by treatment group
(parasitaemia $5000/ml).
Cases Child years Rate (95% CI)
Control 34 52.47 0.65 (0.45–0.91)
SP plus AQ 2 69.04 0.03 (0.00–0.10)
DHA plus PQ 6 68.04 0.09 (0.03–0.19)
SP plus PQ 0 70.17 0.00 (0.00–0.05)
doi:10.1371/journal.pone.0011225.t007
Table 5. Frequency of adverse events by course of treatment.
SPplusAQ DHAplusPQ SPplusPQ Control
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
Sept 61/329 18.5 (14.5,23.2) 62/325 19.1 (15.0,23.8) 72/331 21.8 (17.4,26.6) 77/286 26.9 (21.9,32.5)
Oct 49/324 15.1 (11.4,19.5) 47/316 14.9 (11.1,19.3) 52/328 15.9 (12.1,20.3) 74/280 26.4 (21.4,32.0)
Nov 50/323 15.5 (11.7,19.9) 58/320 18.1 (14.1,22.8) 47/326 14.4 (10.8,18.7) 67/275 24.4 (19.4,29.9)
P-value* 0.29 0.745 0.013 0.491
% refers to the proportion of children who reported any adverse event.
*P-value based on a score test for trend.
doi:10.1371/journal.pone.0011225.t005
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treatment groups and were similar in the three treatment groups.
Minor adverse events were more common in the control group
than in the three treatment groups and these were very likely due
to common childhood illnesses such as malaria as the incidence of
malaria was higher in the control group compared to the three
treatment groups. Previous studies of IPTc in Senegal suggested
that significantly more minor adverse events occur in children who
received amodiaquine-containing preparations than in those who
received artesunate and SP [5]. In contrast a study in Ghana
showed that the incidence of mild adverse events was similar in the
placebo and treatment group including those who received
amodiaquine-containing preparations [6]. These conflicting results
emphasise the need to monitor adverse events if drugs are be used
on a large scale for IPT.
AQ has been used widely for treatment of uncomplicated
malaria in the past and is now used in combination with artesunate
as first line treatment for malaria in several countries in Africa with
no apparent problems over safety. A review of the use of AQ for
treatment of malaria in Africa concluded that it is safe [11].
Measurements of white blood cell count and liver function were
not done to determine the safety of AQ in this study as the serious
adverse effects that have been associated with the prophylactic use
of AQ (agranulocytosis and severe liver toxicity) are considered
rare when it is used for malaria treatment [12]. The principal
active metabolite of amodiaquine has a long half-life (9–18 days)
and this makes it a desirable drug for IPT [13].
SP has been used widely for IPT in infants and in pregnant
women because of its long half-life, safety, wide availability, low-
cost, ease of delivery (a single dose treatment) and a good
acceptability profile. The main concern about the use of SP for
IPT is the propensity for this drug to cause severe skin reactions in
a small proportion of subjects. No adverse cutaneous events were
recorded in children in the current study. The main threat to the
use of SP in IPT regimens comes from increasing resistance to SP,
especially in East Africa. Thus, there is a need to find alternative
drugs for chemoprevention which should, ideally, be used in
combination to reduce the likelihood of the emergence of
resistance.
As there is now increasing evidence that IPT works in infants
and children through its prophylactic effect [14,15] any replace-
ment for SP needs to be long acting, the aim in the case of seasonal
IPTc being to provide a period of chemoprophylaxis during the
time of the year when the risk from malaria is greatest. [14,15].
Thus, if the duration of suppressive chemoprophylaxis is an
important determinant of the efficacy of IPT, drugs with long-half
lives are likely to be more effective. Drugs to be used for IPT
should have a good safety profile, be well tolerated to improve
compliance and acceptability, preferably given as single dose
treatment and affordable.
Piperaquine is attractive as a candidate drug for IPT as it is safe,
with a toxicity profile similar to that of chloroquine, and an
estimated terminal elimination half-life of approximately 17 days.
The combination of piperaquine with SP is a logical one for IPT as
the two drugs have long half lives. However, currently there is no
good manufacturing practice (GMP) product of piperaquine
available for general use. Dihydroartemisinin-piperaquine is an
artemisinin-containing, fixed-combination antimalarial drug, de-
veloped in China, which is safe and highly effective in the
treatment of clinical malaria [16]. However, it is not an ideal
combination for chemoprevention because of the very short half-
life of the artemisinin component, resulting in a significant period
in which new infections are exposed to a single drug. Mefloquine is
a possible candidate for IPT as it has a long half-life, can be given
as a single or split dose and because resistance to mefloquine is not
a significant problem in Africa. It is used for chemoprophylaxis in
short-term non-immune visitors to endemic countries and is
effective when used for IPT in pregnant women [17]. However, a
recent study conducted in Tanzania, showed that mefloquine was
effective when used for IPT in infants but caused vomiting [18].
Mefloquine is relatively expensive and it has not yet been
evaluated for IPT in older children. In the Gambia, SP plus AQ
and SP plus PQ were both highly effective and safe regimens for
IPTC but this might not be the case in countries where the
prevalence of SP resistance is higher than in The Gambia.
For IPTc to be an effective malaria control tool, a reasonable
level of compliance with drug-taking must be maintained with
minimum outside support. Whether this can be achieved will
depend upon the attitude of both the health authorities who
administer the drug and the mothers/guardians who take their
children to the health centre or to the community worker to
receive the tablets. In the current study, compliance was generally
good for all the treatment regimens. However the number of
children who completed all the three doses was significantly less in
the SP plus AQ treatment group compared to the SP plus PQ and
DHA plus PQ groups. It is not clear if the lower compliance was
due to the reduced tolerability of AQ seen in other studies as the
frequency of minor adverse events observed in all the treatments
groups was similar.
A potential weakness of the trial was that it was not a placebo-
controlled trial, the optimum design for most clinical trials, but this
approach was not considered desirable because a trial conducted
along these lines would have resulted in some children not
Table 8. Haematological findings at the end of transmission season cross-sectional survey (December).
SPplusAQ DHAplusPQ SPplusPQ
(n=328) (n =324) (n =330)
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Mean 10.08 9.88,10.28 10.35 10.15,10.55 10.13 9.92,10.33
*Adjusted mean difference 0 0.07 20.14,0.28 0.04 20.17,0.25
P-value (T-test) 0.519 0.718
% Moderate Aneamia (,7g/dL) 0.04 0.02,0.06 0.05 0.03,0.08 0.07 0.04,0.09
RR 1 1.32 0.65,2.68 1.68 0.86,3.28
P-value (Chi-square) 0.43 0.12
*Adjusted for Hb measurement at enrolment.
doi:10.1371/journal.pone.0011225.t008
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receiving IPTc. As IPTc has been shown previously to reduce
morbidity from malaria, it was considered ethically unacceptable
to include a control group. The possibility of unobserved selection
bias and confounding cannot be ruled and the results provided on
the differences in the incidence of clinical episodes of malaria in
the treatment groups compared with the control group must be
treated with caution. However, it appears that all treatment groups
were highly efficacious.
IPT in infants and pregnant women has a major advantage over
IPT in older children in that a delivery system for drug
administration, the reproductive and child health clinic (RCH)
already exists. In contrast, the optimum delivery strategy for IPTc
is not known. A number of studies are under way to identify ways
in which this highly efficacious intervention could be most
effectively delivered.
There may be other groups of children who are at particular
risk from malaria and anaemia who could benefit from IPT. These
include children with sickle cell disease or HIV infection. In older
children, seasonal IPT might improve school attendance and
performance. Thus, there is a need to investigate whether SP plus
AQ, SP plus piperaquine (PQ) and dihydroartemisinin (DHA) plus
PQ might be equally safe and effective when used for IPT in these
groups of children who are at particular risk of malaria.
Supporting Information
Protocol S1
Found at: doi:10.1371/journal.pone.0011225.s001 (0.17 MB
DOC)
Checklist S1 CONSORT checklist.
Found at: doi:10.1371/journal.pone.0011225.s002 (0.05 MB
DOC)
Acknowledgments
We are indebted to the children, their parents, field workers, nurses and
data entry who participated in the study. We also thank the DSMB
members (Chair, Prof. Chris Whitty,), the local safety monitor (Prof.
Ousman Nyang), and Dr Harparkash Kaur and Sigma Tau for study drug
analyses.
Author Contributions
Conceived and designed the experiments: KB PJM BG. Performed the
experiments: KB FA DC. Analyzed the data: KB FA OB CB PJM BG.
Contributed reagents/materials/analysis tools: OB DC. Wrote the paper:
KB FA PJM BG.
References
1. WHO (2000) Experts Committee report on Malaria. Report. Geneva, WHO. pp
1–74.
2. Schellenberg D, Cisse´ B, Menendez C (2006) The IPTi Consortium: research for
policy and action. Trends Parasitol 22: 296–300.
3. Cisse´ B, Sokhna C, Boulanger D, acqueline Milet, El Hadj Baˆ, et al. (2006)
Seasonal intermittent preventive treatment with artesunate and sulfadoxine-
pyrimethamine for prevention of malaria in Senegalese children: a randomised,
placebo-controlled, doubleblind trial. Lancet 367: 659–667.
4. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, et al. (2008) Impact of
intermittent preventive treatment with sulphadoxine-pyrimethamine targeting
the transmission season on the incidence of clinical malaria in children in Mali.
Malar J 7: 123.
5. Sokhna C, Cisse´ B, Baˆ el H, Milligan P, Hallett R, et al. (2008) A trial of the
efficacy, safety and impact on drug resistance of four drug regimens for seasonal
intermittent preventive treatment for malaria in Senegalese children. PLoS ONE
3: e1471.
6. Kweku M, Liu D, Adjuik M, Binka F, Seidu M, et al. (2008) Seasonal
intermittent preventive treatment for the prevention of anaemia and malaria in
Ghanaian children: a randomized, placebo controlled trial. PLoS ONE 3:
e4000.
7. Greenwood BM, Pickering H (1993) A review of the epidemiology and control of
malaria in The Gambia, West Africa. Tran Roy Soc Trop Med Hyg 87 (suppl
2): 3–11.
8. Thomson MC, D’Alessandro U, Bennet S, et al. (1994) Malaria prevalence is
inversely related to vector density in The Gambia, West Africa. Tran Roy Soc
Trop Med Hyg 88: 638–43.
9. Dunyo S, Ord R, Hallett R, Jawara M, Walraven G, et al. (2006) Randomised
Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with
Malaria: Impact against Multidrug-Resistant P. falciparum. PLoS Clin Trials 1:
e14.
10. Greenwood BM, Armstrong JRM (1991) Comparison of two simple methods for
determining malaria parasite density. Tran Roy Soc Trop Med Hyg 85: 186–88.
11. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, et al. (1996) Systematic
review of amodiaquine treatment in uncomplicated malaria. Lancet 348:
1196–201.
12. Phillips-Howard PA, W.L. (1990) Serious adverse drug reactions to pyrimeth-
amine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain.
J R Soc Med 83: 82–5.
13. Pussard E, Verdier F, Faurisson F, Scherrmann JM, Le Bras J, Blayo MC (1987)
Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine
and three regimens for prophylaxis against Plasmodium falciparum malaria.
Eur J Clin Pharmacol 33: 409–414.
14. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Med 2:
e3.
15. Greenwood B (2007) Intermittent preventive antimalarial treatment in infants.
Clin Infect Dis 45: 26–28.
16. Myint HY, Ashley EA, Day NP, Nosten F, White NJ (2007) Efficacy and safety
of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 101: 858–866.
17. Steketee RW, Wirima JJ, Slutsker L, Roberts JM, Khoromana CO, et al. (1996)
Malaria parasite infection during pregnancy and at delivery in mother, placenta,
and newborn: efficacy of chloroquine andmefloquine in rural Malawi. Am J Trop
Med Hyg 55(1 Suppl): 24–32.
18. Gosling R, Chandramohan D, Greenwood B. Drug options for intermittent
preventive treatment for malaria in infants in an area with high resistance to
sulfadoxine/pyrimethamine: an evaluation of short and long-acting antimalarial
drugs, submitted.
Malaria Preventive Treatment
PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11225
